Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974168 | 0.87 | KDM4E (0.35) | HCAR3L3MBTL1TDP1KDM4EPOLB | |
| SCHEMBL2970932 | 0.86 | HCAR3 (0.39) | HCAR3L3MBTL1TDP1KDM4EPOLB | |
| SCHEMBL3423746 | 0.79 | NSD2 (0.41) | HCAR3TDP1KDM4EPOLBNSD2 | |
| Dimethylamine SCHEMBL8760874 | 0.79 | HCAR3 (0.39) | HCAR3L3MBTL1POLBNSD2NCOA1 | |
| SCHEMBL8635142 | 0.78 | GSTP1 (0.43) | HCAR3POLBMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3417440 | 0.78 | NSD2 (0.39) | HCAR3L3MBTL1TDP1KDM4EPOLB | |
| SCHEMBL8760841 | 0.76 | KMT2A (0.38) | L3MBTL1TDP1KDM4EPOLBCTDSP1 | |
| SCHEMBL6570089 | 0.73 | TDP1 (0.47) | L3MBTL1TDP1KDM4EPOLBCTDSP1 | |
| SCHEMBL3420535 | 0.73 | HCAR3 (0.32) | HCAR3MAPT | |
| SCHEMBL29411996 | 0.72 | MAPT (0.47) | HCAR3KDM4EPOLBALDH3A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-14 | — | — | US | disclosed |
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | disclosed |
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
| US-5750782-A | ANTICARCINOGENIC AGENTS, ANTIHYPOXIC AGENTS, PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| EP-0616609-B1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CANCER RES CAMPAIGN TECH (GB) | 1997-06-18 | — | — | EP | disclosed |
| US-5571845-A | Nitroaniline derivatives and their use as anti-tumour agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-11-05 | — | — | US | disclosed |
| EP-0616609-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS. | CANCER RES CAMPAIGN TECH (GB) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993011099-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, PNP | HCAR3 793/4885L3MBTL1 2167/4885TDP1 852/4885 |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, QDPR | HCAR3 589/4885L3MBTL1 1995/4885TDP1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.